R&D News | pharmaphorum

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

News

Humanigen facing bankruptcy as reverse merger fails

Three years ago, Humanigen was riding high with a COVID-19 therapy in late-stage testing and shares worth upwards of $20 apiece.

News

Biogen wields axe again ahead of Leqembi rollout

Biogen has announced another big round of layoffs and cost-cutting, with 1,000 more workers set to lose their jobs after it shed around 900 last year and shelved various R

News

Astellas builds in protein degraders with PeptiDream deal

Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.

News

Small study raises hopes of psilocybin role in anorexia

A small clinical trial has provided the first evidence that the psychedelic medicine psilocybin may have a role to play in the treatment of anorexia nervosa, an eating dis

News

Switch study says patients prefer ViiV’s injectable HIV drug

When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option

MSD, Moderna start phase 3 trial of mRNA cancer jab

Humanigen facing bankruptcy as reverse merger fails

Biogen wields axe again ahead of Leqembi rollout

Astellas builds in protein degraders with PeptiDream deal

Small study raises hopes of psilocybin role in anorexia

Switch study says patients prefer ViiV’s injectable HIV drug

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks